The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Clinical outcomes and markers of treatment response in a randomized phase II study of androgen deprivation therapy with or without palbociclib in RB-intact metastatic hormone-sensitive prostate cancer (mHSPC).
 
Phillip Lee Palmbos
Research Funding - Immunomedics; Roche
Travel, Accommodations, Expenses - Immunomedics
 
Scott A. Tomlins
Employment - Strata Oncology
Leadership - Strata Oncology
Stock and Other Ownership Interests - Javelin Oncology; Strata Oncology
Consulting or Advisory Role - Astellas Medivation; Janssen; Strata Oncology
Research Funding - Astellas Medivation (Inst)
Patents, Royalties, Other Intellectual Property - I am a coauthor on a patent issued to the University of Michigan on ETS gene fusions in prostate cancer. The diagnostic field of use has been licensed to Hologic/Gen-Probe Inc., who has sublicensed some rights to Ventana Medical Systems/Roche.
Travel, Accommodations, Expenses - Strata Oncology
 
Stephanie Daignault
Consulting or Advisory Role - Augmenix; Boston Scientific
Research Funding - Bayer; Pfizer
 
Neeraj Agarwal
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; AstraZeneca; Bayer; Bristol-Myers Squibb; Exelixis; Foundation Medicine; Foundation One Inc; Janssen Oncology; Lilly; Lilly; Lilly; Medivation/Astellas; Merck; Nektar; Novartis; Pfizer; Pfizer; Pharmacyclics
Research Funding - Active Biotech (Inst); Amgen (Inst); AstraZeneca (Inst); Bavarian Nordic (Inst); Bayer (Inst); BN ImmunoTherapeutics (Inst); Bristol-Myers Squibb (Inst); Calithera Biosciences (Inst); Celldex (Inst); Eisai (Inst); Exelixis (Inst); Genentech (Inst); GlaxoSmithKline (Inst); Immunomedics (Inst); Janssen (Inst); Merck (Inst); Newlink Genetics (Inst); Novartis (Inst); Pfizer (Inst); Prometheus (Inst); Rexahn Pharmaceuticals (Inst); Sanofi (Inst); Takeda (Inst); TRACON Pharma (Inst)
 
Przemyslaw Twardowski
Honoraria - Astellas Medivation; Bayer; Genentech/Roche; Janssen; Sanofi/Aventis
Consulting or Advisory Role - Janssen; Sanofi/Aventis
Speakers' Bureau - Astellas Pharma; Bayer; Genentech/Roche; Janssen; Sanofi
 
Alicia K. Morgans
Honoraria - Astellas Pharma; Astellas Scientific and Medical Affairs Inc; AstraZeneca; Bayer; Genentech; Janssen; Janssen Oncology; Sanofi
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bayer; Genentech; Janssen; Sanofi
Research Funding - AstraZeneca; Bayer; Genentech; Seattle Genetics/Astellas
Travel, Accommodations, Expenses - Sanofi
 
William Kevin Kelly
Honoraria - Bayer; Janssen Oncology
Consulting or Advisory Role - Merck Sharp & Dohme
Research Funding - Amgen (Inst); Bayer (Inst); BioClin Therapeutics (Inst); Endocyte (Inst); Exelixis (Inst); Janssen Oncology (Inst); Novartis (Inst); Roche (Inst); Sanofi (Inst); Sarah Cannon Research Institute (Inst); Seagen (Inst)
Travel, Accommodations, Expenses - Janssen Oncology; Merck Sharp & Dohme
 
Vivek Arora
No Relationships to Disclose
 
Emmanuel S. Antonarakis
Honoraria - Astellas Pharma; AstraZeneca; Clovis Oncology; Dendreon; ESSA; Janssen Biotech; Medivation; Merck; Sanofi
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Clovis Oncology; Dendreon; ESSA; Janssen Biotech; Medivation; Merck; Sanofi
Research Funding - Aragon Pharmaceuticals (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Clovis Oncology (Inst); Constellation Pharmaceuticals (Inst); Dendreon (Inst); Exelixis (Inst); Genentech (Inst); Janssen Biotech (Inst); Johnson & Johnson (Inst); Merck (Inst); Millennium (Inst); Novartis (Inst); Sanofi (Inst); Tokai Pharmaceuticals (Inst)
Patents, Royalties, Other Intellectual Property - Co-inventor of a biomarker technology that has been licensed to Qiagen
Travel, Accommodations, Expenses - Dendreon; Medivation; Sanofi
 
Javed Siddiqui
Consulting or Advisory Role - Strata Oncology
 
Dan Robinson
No Relationships to Disclose
 
Karen E. Knudsen
Stock and Other Ownership Interests - Genomic Health; Pfizer
Honoraria - CellCentric; Sanofi
Consulting or Advisory Role - Atrin Pharmaceuticals; CellCentric; Context Therapeutics; Sanofi
Research Funding - Celgene
Travel, Accommodations, Expenses - Genentech; Sanofi
 
Arul Chinnaiyan
Stock and Other Ownership Interests - Esanik; Medsyn Biopharma; OncoFusion Therapeutics; Oncopia Therapeutics; Tempus
Consulting or Advisory Role - Tempus
Patents, Royalties, Other Intellectual Property - University of Michigan royalties.
 
Maha H. A. Hussain
Honoraria - Astellas Pharma; Astellas Pharma; Genentech; MLI PeerView; PER; PER; Phillips Gilmore Oncology; projects in Knowledge; Research to Practice; Research to Practice; Sanofi
Consulting or Advisory Role - AstraZeneca; Bayer; Genentech; Pfizer
Research Funding - AstraZeneca (Inst); Bayer (Inst); Genentech (Inst); PCCTC (Inst); Pfizer (Inst); Pfizer (Inst)
Patents, Royalties, Other Intellectual Property - TITLE: Dual Inhibition of MET and VEGF for the treatment of castration resistant prostate cancer and osteoblastic bone metastases. Applicant/Proprietor Exelexis, Inc. Application No/Patent No. 11764665.4- 1464 Application No/Pat; TITLE: METHOD OF TREATING CANCER Docket No: Serial Number: 224990/10-016P2/311733 61/481/671 Application Filed on: 5/2/2011; TITLE: SYSTEMS AND METHODS FOR TISSUE IMAGING, 3676 Our File: Serial Number: UM-14437/US-1/PRO 60/923,385 UM-14437/US-2/ORD 12/101,753
Travel, Accommodations, Expenses - Astellas Pharma; Bayer; Genentech; Genentech/Roche; Pfizer